Weight management medicine is moving faster than almost any other field in clinical practice. Just a few years ago, the best pharmacological tools available for obesity offered 5–8% total body weight loss. Then tirzepatide arrived, and suddenly 20% was achievable. Now, early data on retatrutide — a drug that adds a third receptor target to the formula — is pushing that figure higher still. But “higher numbers” in a Phase 2 trial and “better medicine” for your patients are not